MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer

Hui-Ming Lin; Iva Nikolic; Jessica Yang; Lesley Castillo; Niantao Deng; Chia Ling Chan; Nicole K. Yeung; Eoin Dodson; Benjamin Elsworth; Calan Spielman; Lisa G. Horvath; Alexander Swarbrick

doi:https://doi.org/10.1038/s41598-018-26050-y

doi.org/10.1038/s41598-018-26050-y

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer

,

,

..., Alexander Swarbrick

38

Scientific Reports4.60

Volume: 8, Issue: 1

Published: May 18, 2018

Abstract

Docetaxel and cabazitaxel are taxane chemotherapy treatments for metastatic castration-resistant prostate cancer (CRPC). However, therapeutic resistance remains a major issue. MicroRNAs are short non-coding RNAs that can silence multiple genes, regulating several signalling pathways simultaneously. Therefore, synthetic microRNAs may have therapeutic potential in CRPC by regulating genes involved in taxane response and minimise compensatory...

Paper Fields

Paper Details

Title

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer

DOI

doi.org/10.1038/s41598-018-26050-y

Published Date

May 18, 2018

Journal

Scientific Reports

Volume

8

Issue

1

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History